1. The Next Generation of Artificial
Intelligence is…
Synthetic Intelligence…
Synthetic Intelligence, Inc.

2. Artificial Intelligence
Platform
Best of breed
World class
Proprietary algorithms

3. First Application
Outsourcing automation of key
assessment & selection
services–
Next generation “Offshoring”

4. Pain
Knowledge Workers are expensive
Trend has been to “offshore” everything
from software development to
telephone based customer service
But this offers only an incremental cost
improvement…

5. Solution
With Synthetic Intelligence, SI replaces
the human with not just a machine, but
a “synthetic human” intelligence
This offers an order of magnitude
improvement in
 cost
 speed
 and accuracy

6. Initial Markets/Roll-out
3 Phase market vertical roll-out
 1st Market Vertical– legal industry
 2nd Market Vertical– recruiting industry
 3rd Market Vertical– VC industry

7. Case Study
Venture Capital-- Implementing SI
achieved the following:
 Shortened time to decision by 10,000%
 Order of magnitude reduction of # of general
partners required for $1B fund
 Probability of success increased from 1 in 10 to 2 in
10, a 100% increase
Same math can be applied to the legal and
recruiting community…

8. Underlying Technology
Combination of best of breed in
 Neural networks
 Artificial intelligence
 Genetic algorithm

9. 2nd Application
Biotechnology drug discovery
Pain: hard to discover/validate drug
targets using conventional methods
Solution: SI solves this by making
decisions on which targets to run with in
all three stages of product
development, pre-clinical & clinical drug
development

10. The Product
Biotech drug discovery
 Based on same platform technology
 Targets will be identified
 Once match is made, will file IND
 Then go to clinical trials in less than 6
months

11. Current IND Product Candidates
C3PO
C3PO is a bi-specific monoclonal antibody targeting a tumor specific
antigen (Galactica) which is over-expressed on adenocarcinomas such as
pancreatic, ovarian and colon cancers.
C3PO is constructed of a proprietary linker joining two antibodies; one
binding to the R2D2 receptor on immune T cells (cytolytic effector) and the
other to Galactica on cancer cells.
Once bound to Galactica on the cancer cells, the proprietary linker facilitates
the killing of primary and metastasized tumor cells by the T cell
C3PO has been shown to be effective in vivo in reducing growth in
colorectal tumors with specificity to those tumors with Galactica positive
antigens

12. Team
CEO– “X” (will disclose name upon
funding) currently leader of Fortune 10
company, willing to leave the role for
this start-up once we receive funding
VP Sales– “Y”, 30 years of sales
experience, very good.
Rest of Org Chart-- TBD

13. Strategic Advisory
Vince Fulmer Board
 MIT Enterprise Forum Chair Emeritus
 entrepreneurial expert
 author of the phrase, “We are students and practitioners
of entrepreneurship. We are specialists in promoting the
field of technology entrepreneurship”
 Weekend warrior and winner of MIT EF body builder
Competition, 2004
Trish Fleming
 Executive Director, MIT Enterprise Forum
 Glad-handing networker extraordinaire
 Fashion Diva, and E! Entertainment fashion
commentator replacement for Joan Rivers

14. SI Revenue Projections
2004 % 2005 % 2006 % 2007 %
Gross Sales $ 2,860,500 100.00% $ 12,763,750 100.00% $ 29,293,500 100.00% $ 56,118,500 100.00%
Cost/ Goods Sold (COGS) 679,050 23.74% 1,821,150 14.27% 2,898,450 9.89% 3,214,350 5.73%
Gross Profit $ 2,181,450 76.26% $ 10,942,600 85.73% $ 26,395,050 90.11% $ 52,904,150 94.27%
Operating Expenses
Salary (Office & Overhead) $ 563,000 19.68% $ 1,099,000 8.61% $ 1,647,000 5.62% $ 1,839,000 3.28%
Payroll (taxes etc.) 197,050 6.89% 384,650 3.01% 576,450 1.97% 643,650 1.15%
Outside Services 34,000 1.19% 300,000 2.35% 750,000 2.56% 350,000 0.62%
Supplies (off and operation) 17,000 0.59% 150,000 1.18% 400,000 1.37% 600,000 1.07%
Repairs/ Maintenance 11,000 0.38% 70,000 0.55% 100,000 0.34% 300,000 0.53%
Advertising 31,000 1.08% 100,000 0.78% 150,000 0.51% 200,000 0.36%
Car, Delivery and Travel 50,000 1.75% 100,000 0.78% 200,000 0.68% 400,000 0.71%
Accounting and Legal 46,000 1.61% 100,000 0.78% 100,000 0.34% 250,000 0.45%
Rent 70,000 2.45% 300,000 2.35% 300,000 1.02% 300,000 0.53%
Telephone 14,750 0.52% 10,000 0.08% 50,000 0.17% 100,000 0.18%
Utilities 12,700 0.44% 30,000 0.24% 40,000 0.14% 60,000 0.11%
Insurance 57,500 2.01% 100,000 0.78% 200,000 0.68% 250,000 0.45%
Misc. & Contingency 37,000 1.29% 200,000 1.57% 200,000 0.68% 300,000 0.53%
Investor Exit Option - 0.00% 3,575,000 28.01% - 0.00% - 0.00%
Acquisition(s) - 0.00% - 0.00% - 0.00% - 0.00%
Eqpt Lease & Netw / Com 135,000 4.72% 250,000 1.96% 250,000 0.85% 750,000 1.34%
(Com Pool + Reserve) (15%) 429,075 15.00% 1,914,563 15.00% 4,394,025 15.00% 8,417,775 15.00%
Total Expenses $ 1,705,075 59.61% $ 8,683,213 68.03% $ 9,357,475 31.94% $ 14,760,425 26.30%
Net Profit Before Tax 476,375 2,259,388 17,037,575 38,143,725
Income Taxes 157,204 745,598 5,622,400 12,587,429
Net Profit After Tax 319,171 1,513,790 11,415,175 25,556,296
Owner Draw/ Dividends 250,000 500,000 5,000,000 15,000,000
Adj. to Retained Earnings $ 69,171 $1,013,790 $ 6,415,175 $ 10,556,296

15. Funding
Currently seeking 15M
 Use of funds
 Accrued wages (particularly founders)
 Infrastructure (office space, furniture, telecom)
 US
 Europe
 Asia
 Bali

16. Funding (continued)
Funding Alternatives
2.5M
Accrued wages (particularly founders)
Infrastructure (office space, furniture, telecom)
US
Bali
 Or, $250,000
Accrued wages (1 founder)
Infrastructure (office space, furniture, telecom)
 Bali

17. Exit
Lifestyle business
If necessary, conversion to 501C3
“.org”
Contact: beachbum@bali.org